Press Releases August 6, 2026 08:00 AM

LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026

LENSAR to announce Q2 2026 results on August 13 with a webcast conference call

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
LNSR

LENSAR, Inc., a US-based medical technology company specializing in robotic laser solutions for cataract treatment, will release its second quarter 2026 financial results before market open on August 13, 2026. The company will host a conference call and webcast to discuss results, corporate highlights, and strategic initiatives.

LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
LNSR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LENSAR focuses on advanced robotic laser technology for cataract surgery.
  • The ALLY Robotic Cataract Laser System integrates AI and proprietary imaging software for improved surgical outcomes.
  • The company aims to enhance operational efficiencies by enabling procedures in sterile ORs or in-office surgical suites.

ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s second quarter 2026 financial results will be released before market open on Thursday, August 13, 2026. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, August 13, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives.

To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. Following the live webcast, an archived version of the call will be available on the website.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Contacts: Lee RothMike Rossi, Interim CFO Burns McClellan for [email protected] [email protected]



Risks

  • Dependence on the adoption and commercial success of the ALLY laser system in a competitive medical technology market.
  • Potential technological or regulatory challenges impacting product development and market entry.
  • Market reaction uncertainty pending the financial results announcement and management commentary.

More from Press Releases

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates Aug 6, 2026 AZIO AI Secures Sales Pipeline for 128 NVIDIA HGX B300 Systems Aug 6, 2026 Banzai International, Inc. Unveils Agentic Platform Strategy, Plans to Change Its Name to Parabolic Technologies, Inc. Aug 6, 2026 Freshworks Achieves FedRAMP® "In Process" Designation for Freshservice, Advancing AI-Powered Service Operations for the Public Sector Aug 6, 2026 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates Aug 6, 2026